Abstract：
BACKGROUND: The number of detected pancreatic neuroendocrine tumours (PanNETs) has been increasing over the last decades. Surgical resection remains the only potentially curative treatment, but the management is still controversial. This study aimed to compare patients after radical PanNET G2 resection to determine the most important predictive factors for relapse.
METHODS: All patients with histologically confirmed PanNET G2 who underwent successful surgery between 2006 and 2020 with the intention of radical treatment were enrolled.
RESULTS: In total, 44 patients were eligible for the analysis. The average follow-up was 8.39 ± 4.5 years. Disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumour was the tail of the pancreas (43.18%), especially in the subgroup with disease recurrence (56.25%). The smallest tumour diameter associated with the PanNET G2 recurrence was 22 mm. The relationship between the largest dimension of the tumour with a division of < 4 cm vs. > 4 cm and the relapse was close to statistical significance. Recurrence was associated with a larger tumour size (p = 0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p = 0.036, V Cramer = 0.371) and disease relapse.
CONCLUSIONS: For the group of PanNET G2 patients after radical surgery, the overall risk of recurrence was 36.36%, with the highest rate in the first 5 years after surgery, but in individual cases it occurred significantly later, even 10 years after surgery. The most important predictive factors of the PanNET G2 recurrence was Ki-67 over 5.75% and size of tumour > 4 cm.
METHODS: All patients with histologically confirmed PanNET G2 who underwent successful surgery between 2006 and 2020 with the intention of radical treatment were enrolled.
RESULTS: In total, 44 patients were eligible for the analysis. The average follow-up was 8.39 ± 4.5 years. Disease recurrence was observed in 16 (36.36%) patients. The dominant location of the primary tumour was the tail of the pancreas (43.18%), especially in the subgroup with disease recurrence (56.25%). The smallest tumour diameter associated with the PanNET G2 recurrence was 22 mm. The relationship between the largest dimension of the tumour with a division of < 4 cm vs. > 4 cm and the relapse was close to statistical significance. Recurrence was associated with a larger tumour size (p = 0.018). There was a statistically significant relationship and a weak correlation between Ki-67 (p = 0.036, V Cramer = 0.371) and disease relapse.
CONCLUSIONS: For the group of PanNET G2 patients after radical surgery, the overall risk of recurrence was 36.36%, with the highest rate in the first 5 years after surgery, but in individual cases it occurred significantly later, even 10 years after surgery. The most important predictive factors of the PanNET G2 recurrence was Ki-67 over 5.75% and size of tumour > 4 cm.
摘要：
背景：在过去的几十年中，检测到的胰腺神经内分泌肿瘤（PanNETs）的数量一直在增加。手术切除仍然是唯一可能治愈的治疗方法，但是管理层仍然存在争议。这项研究旨在比较根治性PanNETG2切除术后的患者，以确定复发的最重要预测因素。
方法：纳入所有经组织学证实的PanNETG2患者，这些患者在2006年至2020年之间成功接受了根治性治疗。
结果：总计，44名患者符合分析条件。平均随访8.39±4.5年。16例（36.36%）患者出现疾病复发。原发肿瘤的主要部位是胰尾(43.18%),尤其是在疾病复发的亚组(56.25%)。与PanNETG2复发相关的最小肿瘤直径为22mm。<4cm的肿瘤最大尺寸与之间的关系>4cm,复发接近统计学意义。复发与较大的肿瘤大小相关（p=0.018）。Ki-67（p=0.036，VCramer=0.371）与疾病复发之间存在统计学上的显着关系和弱相关性。
结论：对于根治性手术后的PanNETG2患者组，总体复发风险为36.36%,手术后的前5年发病率最高，但在个别情况下，它发生得很晚，甚至手术后10年。PanNETG2复发的最重要预测因素是Ki-67超过5.75％，肿瘤大小>4cm。
方法：纳入所有经组织学证实的PanNETG2患者，这些患者在2006年至2020年之间成功接受了根治性治疗。
结果：总计，44名患者符合分析条件。平均随访8.39±4.5年。16例（36.36%）患者出现疾病复发。原发肿瘤的主要部位是胰尾(43.18%),尤其是在疾病复发的亚组(56.25%)。与PanNETG2复发相关的最小肿瘤直径为22mm。<4cm的肿瘤最大尺寸与之间的关系>4cm,复发接近统计学意义。复发与较大的肿瘤大小相关（p=0.018）。Ki-67（p=0.036，VCramer=0.371）与疾病复发之间存在统计学上的显着关系和弱相关性。
结论：对于根治性手术后的PanNETG2患者组，总体复发风险为36.36%,手术后的前5年发病率最高，但在个别情况下，它发生得很晚，甚至手术后10年。PanNETG2复发的最重要预测因素是Ki-67超过5.75％，肿瘤大小>4cm。
